
UPB Stock Forecast & Price Target
UPB Analyst Ratings
Bulls say
Upstream Bio is expected to see strong demand for verekitug upon its potential approval, as the drug has shown promising results in Phase 2 trials for multiple inflammatory diseases. With a strong cash position and plans for strategic development, the company is well-equipped to bring this potentially game-changing treatment to market, which could lead to significant revenue growth and a boost in stock valuation. The positive outlook on Upstream Bio's stock is based on the company's innovative approach to addressing unmet needs in the respiratory disease space, and the potential for verekitug to become a market-leading biologic drug.
Bears say
Upstream Bio is facing elevated financing and commercial risks due to investor sentiment, along with a 13% discount rate, resulting in a reduced price target of $25. The company also faces competition and regulatory risks, as well as potential challenges with maintaining intellectual property protection and setting prices for its products. However, the company's lead candidate verekitug has shown promising results in clinical trials for various inflammatory diseases, and its unique TSLP targeting mechanism may offer a competitive advantage.
This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
UPB Analyst Forecast & Price Prediction
Start investing in UPB
Order type
Buy in
Order amount
Est. shares
0 shares